NEW
Lorviqua

Lorviqua Indications/Uses

lorlatinib

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Full Prescribing Info
Indications/Uses
LORVIQUA as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: alectinib or ceritinib as the first ALK tyrosine kinase inhibitors (TKI) therapy; or crizotinib and at least one other ALK TK1.
This indication is approved under conditional registration which is based on tumor objective response rate and duration of response (see Pharmacology: Pharmacodynamics under Actions). Continued approval for this indication may be based on the outcome of clinical benefit in a confirmatory trial.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in